22.03

1.87% -0.42

Cassava Sciences Inc (SAVA)

Overview News Price History Option Chain Financials Why SAVA Down? Discussions Forecast Stock Split Dividend History

Cassava Sciences Inc stock is currently priced at $22.03, with a 24-hour trading volume of 582.31K. It has seen a -1.87% decreased in the last 24 hours and a -0.54% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $22.13 pivot point. If it approaches the $21.70 support level, significant changes may occur.

Previous Close:

$22.45

Open:

$22.74

24h Volume:

582.31K

Market Cap:

$1.06B

Revenue:

Net Income/Loss:

$-97.22M

P/E Ratio:

-10.06

EPS:

-2.19

Net Cash Flow:

$-82.44M

1W Performance:

+1.45%

1M Performance:

-0.54%

6M Performance:

+5.76%

1Y Performance:

-2.99%

1D Range:

$21.55

$22.90

52W Range:

$12.32

$32.10

Cassava Sciences Inc Stock (SAVA) Company Profile

Name

Cassava Sciences Inc

Sector

Healthcare (1198)

Industry

Biotechnology (691)

Phone

512-501-2444

Address

7801 North Capital of Texas Highway, Suite 260, Austin, TX

Employee

Twitter

Next Earnings Date

2024-05-09

Latest SEC Filings

SAVA's Discussions on Twitter

Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-16-22	Downgrade	B. Riley Securities	Buy → Neutral
Jul-15-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jul-07-21	Reiterated	Maxim Group	Buy
Apr-27-21	Initiated	B. Riley Securities	Buy
Feb-16-21	Reiterated	H.C. Wainwright	Buy
Oct-23-20	Initiated	Cantor Fitzgerald	Overweight
Sep-23-20	Upgrade	H.C. Wainwright	Neutral → Buy
May-18-20	Downgrade	H.C. Wainwright	Buy → Neutral
May-15-20	Downgrade	Maxim Group	Buy → Hold
Jan-10-20	Reiterated	Maxim Group	Buy

View All

Cassava Sciences Inc Stock (SAVA) Latest News

Quest Partners LLC Takes $118000 Position in Cassava Sciences, Inc. (NASDAQ:SAVA) - Defense World

Defense World

How to Take Advantage of moves in (SAVA) - Stock Traders Daily

Stock Traders Daily

Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is ... - Yahoo Lifestyle UK

Yahoo Lifestyle UK

Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know - Yahoo New Zealand News

Yahoo New Zealand News

Swiss National Bank Decreases Stock Holdings in Cassava Sciences, Inc. (NASDAQ:SAVA) - Defense World

Defense World

Cassava (SAVA) Down on Report of SEC Investigation Into AD Program - Yahoo Lifestyle UK

Yahoo Lifestyle UK

Cassava Sciences Inc Stock (SAVA) Financials Data

Cassava Sciences Inc (SAVA) Net Income 2024

SAVA net income (TTM) was -$97.22 million for the quarter ending December 31, 2023, a -27.50% decrease year-over-year.

Cassava Sciences Inc (SAVA) Cash Flow 2024

SAVA recorded a free cash flow (TTM) of -$82.44 million for the quarter ending December 31, 2023, a -2.76% decrease year-over-year.

Cassava Sciences Inc (SAVA) Earnings per Share 2024

SAVA earnings per share (TTM) was -$2.32 for the quarter ending December 31, 2023, a -22.11% decline year-over-year.

Cassava Sciences Inc Stock (SAVA) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Barry Richard	Director	Apr 23 '24	Option Exercise	22.00	176,085	3,873,870	469,562
Kupiec James William	Chief Medical Officer	Apr 18 '24	Option Exercise	22.00	1,500	33,000	4,000
Schoen Eric	Chief Financial Officer	Apr 17 '24	Option Exercise	22.00	1,500	33,000	21,300
ROBERTSON SANFORD	Director	Aug 23 '23	Buy	17.45	30,000	523,500	886,851
Barry Richard	Director	Aug 22 '23	Buy	16.65	16,571	275,907	293,477
Barry Richard	Director	Aug 21 '23	Buy	16.80	1,906	32,021	276,906
SCANNON PATRICK J MD PHD	Director	Jun 12 '23	Option Exercise	0.95	1,000	950	1,000

Cassava Sciences, Inc., a clinical-stage drug development company, develops drugs for nervous system disorders. The company's lead therapeutic product candidate PTI-125, a small molecule drug that is in Phase II clinical trial for the treatment of Alzheimer's disease. It is also developing PTI-125Dx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.